United States Biotechnology & Medical Research

Forte Biosciences, Inc. (FBRX)

Track

Track

Forte Biosciences recorded its most recent insider trading activity on December 30, 2025, when Chief Financial Officer Antony A. Riley executed a purchase of 9,680 shares. This transaction follows a series of historical acquisitions by company leadership, reflecting consistent buying patterns over previous periods without any reported sales.
Ticker: FBRX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Forte Biosciences, Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.4
Riley Antony A CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
307.78
Quantity 98,438 +23.6%
Value US$1,957,624
2.4
Riley Antony A CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
406.41
Quantity 9,910 -31.2%
Value US$4,911,483
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
165.82
Quantity 86,075 +47.8%
Value US$1,631,281
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.72
Quantity 10,000 +0.6%
Value US$7,200
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.70
Quantity 10,520 +0.6%
Value US$7,351
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.65
Quantity 4,776 +0.3%
Value US$3,088
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.65
Quantity 25,000 +1.4%
Value US$16,188
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.62
Quantity 15,000 +0.9%
Value US$9,300
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.58
Quantity 36,203 +2.1%
Value US$21,168
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.43
Quantity 400 +0.0%
Value US$172
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.43
Quantity 100 +0.0%
Value US$43
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.43
Quantity 1,566 +0.1%
Value US$673
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
0.44
Quantity 5,300 +0.3%
Value US$2,332
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
1.07
Quantity 44,024 +3.3%
Value US$47,000
2.9
Wagner Paul A. See Remarks Executive Director
Transaction date
Purchase
Price
1.03
Quantity 55,976 +4.4%
Value US$57,672
2.6
Oliveira Steven Michael Large shareholder
Transaction date
Purchase
Price
1.19
Quantity 74,301 +2.7%
Value US$88,418
2.6
Oliveira Steven Michael Large shareholder
Transaction date
Purchase
Price
1.35
Quantity 65,149 +2.4%
Value US$87,756
2.7
Hasnain Faheem
Transaction date
Purchase
Price
5.15
Quantity 250 +0.1%
Value US$1,287
2.7
Hasnain Faheem
Transaction date
Purchase
Price
5.30
Quantity 3,890 +1.6%
Value US$20,613
2.7
Hasnain Faheem
Transaction date
Purchase
Price
4.59
Quantity 38,860 +19.2%
Value US$178,414
Duvall Martin J Chief Executive Officer Executive Director
Transaction date
Planned purchase
Price
4.34
Quantity 5,000 +58.1%
Value US$21,678
3.7
FOLETTA MARK G EVP & Chief Financial Officer Officer
Transaction date
Planned purchase
Price
4.30
Quantity 5,000 +49.8%
Value US$21,475
GRUBER HARRY E President, Science&Innovation Executive Director
Transaction date
Planned purchase
Price
4.56
Quantity 5,000 +105.4%
Value US$22,782
Das Asha SVP & Chief Medical Officer
Transaction date
Purchase
Price
10.00
Quantity 2,500 +inf%
Value US$25,000
1.7
SCHIMMEL PAUL
Transaction date
Purchase
Price
10.00
Quantity 10,000 +276.0%
Value US$100,000
GRUBER HARRY E President, Research & Devel Executive Director
Transaction date
Purchase
Price
10.00
Quantity 25,000 +6.4%
Value US$250,000
3.7
FOLETTA MARK G EVP & Chief Financial Officer
Transaction date
Purchase
Price
10.00
Quantity 5,000 +inf%
Value US$50,000
2.7
Hasnain Faheem
Transaction date
Purchase
Price
10.00
Quantity 100,000 +97.2%
Value US$1,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-02 2025-12-30 B Purchase
2.4
Riley Antony A

CHIEF FINANCIAL OFFICER

Officer
98,438 +23.6%
307.78
US$1,957,624 		98,438 +23.6% 307.78 US$1,957,624
2024-11-22 2024-11-21 B Purchase
2.4
Riley Antony A

CHIEF FINANCIAL OFFICER

Officer
9,910 -31.2%
406.41
US$4,911,483 		9,910 -31.2% 406.41 US$4,911,483
2023-12-20 2023-12-18 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
86,075 +47.8%
165.82
US$1,631,281 		86,075 +47.8% 165.82 US$1,631,281
2023-12-15 2023-12-14 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
10,000 +0.6%
0.72
US$7,200 		10,000 +0.6% 0.72 US$7,200
2023-12-15 2023-12-13 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
10,520 +0.6%
0.70
US$7,351 		10,520 +0.6% 0.70 US$7,351
2023-12-12 2023-12-12 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
4,776 +0.3%
0.65
US$3,088 		4,776 +0.3% 0.65 US$3,088
2023-12-12 2023-12-11 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
25,000 +1.4%
0.65
US$16,188 		25,000 +1.4% 0.65 US$16,188
2023-12-08 2023-12-08 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
15,000 +0.9%
0.62
US$9,300 		15,000 +0.9% 0.62 US$9,300
2023-12-08 2023-12-07 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
36,203 +2.1%
0.58
US$21,168 		36,203 +2.1% 0.58 US$21,168
2023-11-22 2023-11-22 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
400 +0.0%
0.43
US$172 		400 +0.0% 0.43 US$172
2023-11-22 2023-11-20 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
100 +0.0%
0.43
US$43 		100 +0.0% 0.43 US$43
2023-11-22 2023-11-20 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
1,566 +0.1%
0.43
US$673 		1,566 +0.1% 0.43 US$673
2023-11-22 2023-11-20 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
5,300 +0.3%
0.44
US$2,332 		5,300 +0.3% 0.44 US$2,332
2022-12-19 2022-12-16 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
44,024 +3.3%
1.07
US$47,000 		44,024 +3.3% 1.07 US$47,000
2022-12-19 2022-12-15 B Purchase
2.9
Wagner Paul A.

See Remarks

Executive Director
55,976 +4.4%
1.03
US$57,672 		55,976 +4.4% 1.03 US$57,672
2020-04-14 2020-04-14 B Purchase
2.6
Oliveira Steven Michael
Large shareholder
74,301 +2.7%
1.19
US$88,418 		74,301 +2.7% 1.19 US$88,418
2020-03-03 2020-03-02 B Purchase
2.6
Oliveira Steven Michael
Large shareholder
65,149 +2.4%
1.35
US$87,756 		65,149 +2.4% 1.35 US$87,756
2019-06-03 2019-05-30 B Purchase
2.7
Hasnain Faheem
250 +0.1%
5.15
US$1,287 		250 +0.1% 5.15 US$1,287
2019-06-03 2019-05-30 B Purchase
2.7
Hasnain Faheem
3,890 +1.6%
5.30
US$20,613 		3,890 +1.6% 5.30 US$20,613
2019-06-03 2019-05-30 B Purchase
2.7
Hasnain Faheem
38,860 +19.2%
4.59
US$178,414 		38,860 +19.2% 4.59 US$178,414
2019-05-29 2019-05-28 PP Planned purchase
Duvall Martin J

Chief Executive Officer

Executive Director
5,000 +58.1%
4.34
US$21,678 		5,000 +58.1% 4.34 US$21,678
2019-05-29 2019-05-28 PP Planned purchase
3.7
FOLETTA MARK G

EVP & Chief Financial Officer

Officer
5,000 +49.8%
4.30
US$21,475 		5,000 +49.8% 4.30 US$21,475
2019-05-29 2019-05-24 PP Planned purchase
GRUBER HARRY E

President, Science&Innovation

Executive Director
5,000 +105.4%
4.56
US$22,782 		5,000 +105.4% 4.56 US$22,782
2017-04-21 2017-04-19 B Purchase
Das Asha

SVP & Chief Medical Officer
2,500 +inf%
10.00
US$25,000 		2,500 +inf% 10.00 US$25,000
2017-04-21 2017-04-19 B Purchase
1.7
SCHIMMEL PAUL
10,000 +276.0%
10.00
US$100,000 		10,000 +276.0% 10.00 US$100,000
2017-04-21 2017-04-19 B Purchase
GRUBER HARRY E

President, Research & Devel

Executive Director
25,000 +6.4%
10.00
US$250,000 		25,000 +6.4% 10.00 US$250,000
2017-04-21 2017-04-19 B Purchase
3.7
FOLETTA MARK G

EVP & Chief Financial Officer
5,000 +inf%
10.00
US$50,000 		5,000 +inf% 10.00 US$50,000
2017-04-21 2017-04-19 B Purchase
2.7
Hasnain Faheem
100,000 +97.2%
10.00
US$1,000,000 		100,000 +97.2% 10.00 US$1,000,000
Explore more

More insider trading research around Forte Biosciences, Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America